Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS)
- PMID: 31320445
- PMCID: PMC6702603
- DOI: 10.2337/dc19-0244
Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS)
Abstract
Objective: Regression from prediabetes to normal glucose regulation (NGR) was associated with reduced incidence of diabetes by 56% over 10 years in participants in the Diabetes Prevention Program Outcomes Study (DPPOS). In an observational analysis, we examined whether regression to NGR also reduced risk for microvascular disease (MVD).
Research design and methods: Generalized estimating equations were used to examine the prevalence of aggregate MVD at DPPOS year 11 in people who regressed to NGR at least once (vs. never) during the Diabetes Prevention Program (DPP). Logistic regression assessed the relationship of NGR with retinopathy, nephropathy, and neuropathy, individually. Generalized additive models fit smoothing splines to describe the relationship between average A1C during follow-up and MVD (and its subtypes) at the end of follow-up.
Results: Regression to NGR was associated with lower prevalence of aggregate MVD in models adjusted for age, sex, race/ethnicity, baseline A1C, and treatment arm (odds ratio [OR] 0.78, 95% CI 0.65-0.78, P = 0.011). However, this association was lost in models that included average A1C during follow-up (OR 0.95, 95% CI 0.78-1.16, P = 0.63) or diabetes status at the end of follow-up (OR 0.92, 95% CI 0.75-1.12, P = 0.40). Similar results were observed in examination of the association between regression to NGR and prevalence of nephropathy and retinopathy, individually. Risk for aggregate MVD, nephropathy, and retinopathy increased across the A1C range.
Conclusions: Regression to NGR is associated with a lower prevalence of aggregate MVD, nephropathy, and retinopathy, primarily due to lower glycemic exposure over time. Differential risk for the MVD subtypes begins in the prediabetes A1C range.
Trial registration: ClinicalTrials.gov NCT00004992 NCT00038727.
© 2019 by the American Diabetes Association.
Figures


References
-
- Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group . Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243–2251 - PMC - PubMed
-
- Perreault L, Temprosa M, Mather KJ, et al. .; Diabetes Prevention Program Research Group . Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program Outcomes Study. Diabetes Care 2014;37:2622–2631 - PMC - PubMed
-
- American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl. 1):S5–S10 - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U01 DK048412/DK/NIDDK NIH HHS/United States
- U01 DK048375/DK/NIDDK NIH HHS/United States
- U01 DK048434/DK/NIDDK NIH HHS/United States
- U01 DK048413/DK/NIDDK NIH HHS/United States
- R01 DK078907/DK/NIDDK NIH HHS/United States
- M01 RR016587/RR/NCRR NIH HHS/United States
- U01 DK048339/DK/NIDDK NIH HHS/United States
- U01 DK048443/DK/NIDDK NIH HHS/United States
- U01 DK048400/DK/NIDDK NIH HHS/United States
- U01 DK048468/DK/NIDDK NIH HHS/United States
- U01 DK048404/DK/NIDDK NIH HHS/United States
- U01 DK048407/DK/NIDDK NIH HHS/United States
- U01 DK048437/DK/NIDDK NIH HHS/United States
- U01 DK048406/DK/NIDDK NIH HHS/United States
- U01 DK048397/DK/NIDDK NIH HHS/United States
- U01 DK048381/DK/NIDDK NIH HHS/United States
- U01 DK048514/DK/NIDDK NIH HHS/United States
- U01 DK048485/DK/NIDDK NIH HHS/United States
- UL1 TR002345/TR/NCATS NIH HHS/United States
- U01 DK048489/DK/NIDDK NIH HHS/United States
- U01 DK048349/DK/NIDDK NIH HHS/United States
- U01 DK048377/DK/NIDDK NIH HHS/United States
- P30 DK017047/DK/NIDDK NIH HHS/United States